Natera is facing a class action lawsuit in the Northern District of California alleging false and misleading marketing of its preimplantation genetic testing for aneuploidy, Spectrum PGT-A. Plaintiffs claim the company sold the test as “proven, accurate, and reliable” for improving miscarriage and live birth outcomes despite disputed evidence. The filing also alleges that PGT-A should be characterized as unproven and unreliable, with the lawsuit citing studies showing no difference in pregnancy, miscarriage, or live birth rates between IVF cycles using or not using PGT-A. It further points to professional guidance—ASRM/SART and ACOG opinions—describing insufficient evidence for routine use. Natera discontinued its Spectrum PGT-A test before the suit. Even so, the case targets advertising and consumer protection claims tied to how the test was promoted during its commercial period, with potential implications for fertility diagnostics compliance nationwide.